N/A
Completed N=146
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
Source: ClinicalTrials.gov NCT00211510 ↗Enrolled (actual)
146
Serious AEs
15.1%
Results posted
Apr 2011
Primary outcomePrimary: Change in A1c From Baseline to 26 Weeks — -0.72; -0.58 Percent glycated hemoglobin
Summary
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in A1c From Baseline to 26 Weeks |
-0.72; -0.58 | — |
| SECONDARY Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26 |
11; 3 | — |
| SECONDARY Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26 |
-0.07; 0.281 | — |
| SECONDARY Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26 |
-10.2; -9.2 | — |
| SECONDARY Glucose Sensor Accuracy as Measured in the 722 Group |
95.9; NA | — |
| SECONDARY Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups |
-0.07; -0.22 | — |
Eligibility Criteria
Inclusion Criteria
- Age 12 - 80 years
- Type 1 Diabetes Mellitus diagnosed at least 1 year ago
- Using insulin infusion pump for past 6 months minimum
- Performing minimum 4 blood glucose tests per day
- Agree to treat to A1c targets
- Read and understand English
Exclusion Criteria
- Pregnant or planning pregnancy
- History of unresolved tape allergy or skin conditions
Data sourced from ClinicalTrials.gov (NCT00211510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.